1. Bhargava HN, Das S, Bansinath M. Proliferation of thyrotropin releasing hormone receptors in specific brain regions during the development of hypertension in spontaneously hypertensive rats. Peptides 1987;8:231–235.
2. Bruhn TO, Jackson IM. Abnormalities of the thyroid hormone negative feedback regulation of TSH secretion in spontaneously hypertensive rats. Regul Pept 1992;38:221–230.
3. García SI, Alvarez AL, Porto PI, Garfunkel VM, Finkielman S, Pirola CJ. Antisense inhibition of thyrotropin-releasing hormone reduces arterial blood pressure in spontaneously hypertensive rats. Hypertension 2001;37(2 Pt 2):365–370.
4. García SI, Porto PI, Alvarez AL, et al. Central overexpression of the TRH precursor gene induces hypertension in rats: antisense reversal. Hypertension 1997;30(3 Pt 2):759–766.
5. Zwaveling J, Pfaffendorf M, van Zwieten PA. The direct effects of thyroid hormones on rat mesenteric resistance arteries. Fundam Clin Pharmacol 1997;11:41–46.
6. Pereira RC, Jorgetti V, Canalis E. Triiodothyronine induces collagenase-3 and gelatinase B expression in murine osteoblasts. Am J Physiol 1999;277:E496–E504.
7. Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab 2002;87:1996–2000.
8. Streeten DH, Anderson GH Jr, Howland T, Chiang R, Smulyan H. Effects of thyroid function on blood pressure. Recognition of hypothyroid hypertension. Hypertension 1988;11:78–83.
9. Kotsis V, Alevizaki M, Stabouli S, et al. Hypertension and hypothyroidism: results from an ambulatory blood pressure monitoring study. J Hypertens 2007;25:993–999.
10. Armigliato M, Paolini R, Aggio S, et al. Hyperthyroidism as a cause of pulmonary arterial hypertension: a prospective study. Angiology 2006;57:600–606.
11. Grineva E, Babenko A, Vahrameeva N, et al. Type 2 deiodinase Thr92Ala polymorphism impact on clinical course and myocardial remodeling in patients with Graves’ disease. Cell Cycle 2009;8:2565–2569.
12. Peeters RP, van Toor H, Klootwijk W, et al. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab 2003;88:2880–2888.
13. Nair S, Muller YL, Ortega E, Kobes S, Bogardus C, Baier LJ. Association analyses of variants in the DIO2 gene with early-onset type 2 diabetes mellitus in Pima Indians. Thyroid 2012;22:80–87.
14. Gumieniak O, Perlstein TS, Williams JS, et al. Ala92 type 2 deiodinase allele increases risk for the development of hypertension. Hypertension 2007;49:461–466.
15. Mizuma H, Murakami M, Mori M. Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase. Circ Res 2001;88:313–318.
16. Ferdous A, Wang ZV, Luo Y, et al. FoxO1-Dio2 signaling axis governs cardiomyocyte thyroid hormone metabolism and hypertrophic growth. Nat Commun 2020;11:2551.
17. Canani LH, Leie MA, Machado WE, Capp C, Maia AL. Type 2 deiodinase Thr92Ala polymorphism is not associated with arterial hypertension in type 2 diabetes mellitus patients. Hypertension 2007;49:e47.
18. Maia AL, Hwang SJ, Levy D, Larson MG, Larsen PR, Fox CS. Lack of association between the type 2 deiodinase A/G polymorphism and hypertensive traits: the Framingham Heart Study. Hypertension 2008;51:e22–e23.
19. Gereben B, McAninch EA, Ribeiro MO, Bianco AC. Scope and limitations of iodothyronine deiodinases in hypothyroidism. Nat Rev Endocrinol 2015;11:642–652.
20. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest 2006;116:2571–2579.
21. Madan R, Celi FS. Combination therapy for hypothyroidism: rationale, therapeutic goals, and design. Front Endocrinol (Lausanne) 2020;11:371.
22. Carle A, Faber J, Steffensen R, Laurberg P, Nygaard B. Hypothyroid patients encoding combined MCT10 and DIO2 gene polymorphisms may prefer L-T3 + L-T4 combination treatment: data using a blind, randomized, clinical study. Eur Thyroid J 2017;6:143–151.
23. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab 2009;94:1623–1629.
24. Jeon J, Jung KJ, Jee SH. Waist circumference trajectories and risk of type 2 diabetes mellitus in Korean population: the Korean genome and epidemiology study (KoGES). BMC Public Health 2019;19:741.
25. Kim Y, Han BG, KoGES Group. Cohort profile: the Korean Genome and Epidemiology Study (KoGES) consortium. Int J Epidemiol 2017;46:e20.
26. Jo S, Fonseca TL, Bocco BM, et al. Type 2 deiodinase polymorphism causes ER stress and hypothyroidism in the brain. J Clin Invest 2019;129:230–245.
27. Lee SK, Kim SH, Cho GY, et al. Obesity phenotype and incident hypertension: a prospective community-based cohort study. J Hypertens 2013;31:145–151.
28. Estivalet AA, Leiria LB, Dora JM, et al. D2 Thr92Ala and PPARγ2 Pro12Ala polymorphisms interact in the modulation of insulin resistance in type 2 diabetic patients. Obesity (Silver Spring) 2011;19:825–832.
29. Korean Society Hypertension (KSH); Hypertension Epidemiology Research Working Group; Kim HC, Cho MC. Korea hypertension fact sheet 2018. Clin Hypertens 2018;24:13.
30. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol 2018;71:2199–2269.
31. Chalmers J, MacMahon S, Mancia G, et al. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Guidelines Sub-committee of the World Health Organization. Clin Exp Hypertens 1999;21:1009–1060.
32. Kang YE, Kang YM, Park B, Shong M, Yi HS. Type 2 deiodinase Thr92Ala polymorphism is associated with a reduction in bone mineral density: a community-based korean genome and epidemiology study. Clin Endocrinol (Oxf) 2020;93:238–247.
33. Cho YY, Kim HJ, Jang HW, et al. The relationship of 19 functional polymorphisms in iodothyronine deiodinase and psychological well-being in hypothyroid patients. Endocrine 2017;57:115–124.
34. Heemstra KA, Hoftijzer H, van der Deure WM, et al. The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. J Bone Miner Res 2010;25:1385–1391.
35. Meulenbelt I, Min JL, Bos S, et al. Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis. Hum Mol Genet 2008;17:1867–1875.
36. Hiroi Y, Kudoh S, Monzen K, et al. Tbx5 associates with Nkx2–5 and synergistically promotes cardiomyocyte differentiation. Nat Genet 2001;28:276–280.
37. Dentice M, Morisco C, Vitale M, Rossi G, Fenzi G, Salvatore D. The different cardiac expression of the type 2 iodothyronine deiodinase gene between human and rat is related to the differential response of the Dio2 genes to Nkx-2.5 and GATA-4 transcription factors. Mol Endocrinol 2003;17:1508–1521.
38. Mentuccia D, Proietti-Pannunzi L, Tanner K, et al. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes 2002;51:880–883.
39. Grarup N, Andersen MK, Andreasen CH, et al. Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects. J Clin Endocrinol Metab 2007;92:363–366.
40. Williams GR, Bassett JH. Deiodinases: the balance of thyroid hormone: local control of thyroid hormone action: role of type 2 deiodinase. J Endocrinol 2011;209:261–272.
41. Maia AL, Dupuis J, Manning A, et al. The type 2 deiodinase (DIO2) A/G polymorphism is not associated with glycemic traits: the Framingham Heart Study. Thyroid 2007;17:199–202.
42. Brozaitiene J, Skiriute D, Burkauskas J, et al. Deiodinases, organic anion transporter polypeptide polymorphisms, and thyroid hormones in patients with myocardial infarction. Genet Test Mol Biomarkers 2018;22:270–278.
43. AlRasheed MM, AlAnzi A, AlShalhoub R, Abanmy N, Bakheet D. A study of the role of DIO1 and DIO2 polymorphism in thyroid cancer and drug response to therapy in the Saudi population. Saudi Pharm J 2019;27:841–845.
44. Castagna MG, Dentice M, Cantara S, et al. DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 levels in thyroid-deficient patients. J Clin Endocrinol Metab 2017;102:1623–1630.
留言 (0)